Author: Sharad Vadehra and Arpita Arora.

August 6, 2025
Blog
No Comments

Can a Biosimilar Reference Product Trigger Infringement?

Introduction In a recent development for biologics patents in India, the Delhi High Court has granted interim relief to E.R. Squibb in their infringement suit1 against Zydus Lifesciences. The suit concerns IN 340060, which claims the monoclonal antibody Nivolumab—commercially known as Opdivo®—used in immunotherapy for various cancers. On July 18, 2025, the Court restrained Zydus […]

November 6, 2024
Blog
No Comments

Intellectual Property Essentials for Indian Startups

Introduction India has swiftly emerged as one of the world’s top startup ecosystems, driven by government policies, a large and youthful population, and increasing digital penetration. According to the Economic Survey, the country now ranks as the third-largest startup ecosystem globally, behind the United States and China. Notably, Indian startups are recognized for their innovation, […]

September 18, 2024
Blog
No Comments

Biosimilars in India: Regulatory, Legal and Industry Landscape

Introduction Biosimilars, a category of biologic medications, are offering new hope for patients by providing cost-effective alternatives to original biologics, which are often expensive and complex. Biosimilars are a type of biologic medication that is safe and effective for treating many illnesses. A biosimilar and its original biologic have the same treatment risks and benefits. […]

June 27, 2024
Blog
No Comments

From Obvious to Inventive: Lessons from DHC’s Alimentary Health Ruling

Introduction In a recent judgement dated May 14, 2024, in Alimentary Health Limited vs. Controller of Patents and Design[i], the Delhi High Court set aside a patent refusal order issued by the Indian Patent Office in respect of Indian patent application 3989/DELNP/2012, which had been denied, stating that the invention lacked an inventive step and […]